Tech Company Financing Transactions
NexImmune Funding Round
NexImmune, operating out of Gaithersburg, secured $3 million from New Enterprise Associates, Amgen Ventures and Pfizer Venture Investments.
Transaction Overview
Company Name
Announced On
7/23/2014
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
New Enterprise Associates (Lead Investor) (James Barrett)
Amgen Ventures (Janis Naeve)
Proceeds Purpose
Proceeds from this financing will be used to support pre-clinical development of the companys first product, AIM 101, an artificial Antigen Presenting Cell (aAPC) for the treatment of cancer.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9119 Gaither Rd.
Gaithersburg, MD 20877
USA
Gaithersburg, MD 20877
USA
Phone
Website
Email Address
Overview
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the development of immuno-therapies for a variety of cancers and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Carmer
Chief Financial Officer
Alain Cappeluti
Chief Operating Officer
Kristi Jones
Vice President
Alex Matschiner
Vice President
Mathias Oelke
VP - Bus. Development
Naimish Pandya
VP - Engineering
Daniel Bednárik
Browse more venture capital transactions:
Prev: 7/23/2014: EdgeWave venture capital transaction
Next: 7/23/2014: Karmaloop venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs